Syngene International , a leading contract research organization, has reported a strong start to the fiscal year 2026, with revenue from operations growing by 11% year-on-year to Rs. 875.00 crore in the first quarter. The company's financial results, released on July 23, 2025, showcase resilience and continued momentum in its business operations.

Financial Highlights

• Revenue from operations increased to Rs. 875.00 crore, up from Rs. 790.00 crore in Q1 FY25
• Reported EBITDA rose by 19% year-on-year to Rs. 224.00 crore
• EBITDA margin improved to 25%, compared to 23% in the same quarter last year
• Profit After Tax (PAT) before exceptional items surged by 59% to Rs. 87.00 crore

Operational Highlights

Syngene's performance was driven by continued conversion of pilot programs into longer-term contracts within its Research Services business. The company also made progress in its Biologics manufacturing division, with the start of operations at the Unit III facility in Bengaluru and advancing preparations for the Bayview facility in the U.S.

Peter Bains, Managing Director and CEO of Syngene International, commented on the results, stating, "We are pleased with the growth performance in the first quarter, which is aligned with our expectations. While we remain mindful of ongoing macroeconomic factors, we maintain a confident outlook."

Strategic Developments

The company has strengthened its scientific capabilities by inaugurating a state-of-the-art, dedicated peptide laboratory. This addition complements Syngene's existing expertise in monoclonal antibodies, Antibody-Drug Conjugates, Oligonucleotides, and PROTACs.

Regulatory Compliance and Quality Assurance

Syngene successfully completed a USFDA Good Clinical Practices (GCP) inspection of its Human Pharmacology Unit with no observations. The company's Biologics facility at Biocon Park received an Establishment Inspection Report (EIR) with a favorable Voluntary Action Indicated (VAI) outcome. Additionally, Syngene concluded over 20 client and regulatory audits in Q1 FY26, reinforcing its commitment to global quality and integrity standards.

Sustainability Recognition

Syngene was recognized by TIME magazine and Statista as one of the World's Most Sustainable Companies in 2025. The company ranked #1 in India among companies in the pharma and biotech sectors and was placed in the top 20 life science companies globally.

Outlook

Deepak Jain, Chief Financial Officer of Syngene International, expressed satisfaction with the company's financial performance and stated, "We continue to maintain a robust balance sheet enabling us to invest in technology and capabilities to strengthen our customer offerings. While keeping a close watch on market trends, we remain on course to deliver in line with our stated guidance for the year."

As Syngene International continues to navigate the evolving economic landscape, the company's strong start to FY26 and its reaffirmation of annual guidance demonstrate its resilience and strategic focus on long-term growth in the contract research and manufacturing services sector.

Syngene International Limited , a leading contract research and manufacturing services company, has reported strong financial results for the first quarter, demonstrating robust growth and operational progress.

Financial Highlights

Syngene's consolidated revenue from operations for Q1 increased by 11% year-on-year to Rs. 875.00 crores, up from Rs. 790.00 crores in the same quarter last year. The company's reported EBITDA saw a significant jump of 19%, reaching Rs. 224.00 crores, with the EBITDA margin improving to 25% from 23% in the previous year.

Notably, the reported Profit After Tax (PAT) showed a remarkable increase of 59%, rising to Rs. 87.00 crores compared to Rs. 54.00 crores in Q1 of the previous year. This substantial growth in profitability underscores the company's operational efficiency and strong market position.

All figures in Rs. crores, except percentages

Operational Highlights

Syngene has made significant strides in expanding its capabilities and facilities during the quarter:

1. Biologics Manufacturing Expansion: The company commenced operations at its Unit III facility in Bengaluru, enhancing its biologics manufacturing capacity.

2. US Facility Progress: Preparations are underway to start operations at the Bayview facility in the United States later this year, marking an important step in Syngene's global expansion.

3. New Peptide Laboratory: Syngene inaugurated a state-of-the-art, dedicated peptide laboratory, broadening its scientific platform capabilities.

4. Regulatory Compliance: The company successfully completed a USFDA Good Clinical Practices inspection with no observations, reinforcing its commitment to quality and regulatory standards.

Management Commentary

Peter Bains, Managing Director and CEO of Syngene International Limited, commented on the results: "We are pleased with the growth performance in the first quarter, which is aligned with our expectations. Continued conversion of pilot programs into longer-term contracts within our Research Services business was the main driver underpinning this momentum."

Deepak Jain, Chief Financial Officer, added: "Operating EBITDA margins came at around 24%, driven by both revenue growth and a focus on cost optimization. The current quarter's PAT includes a tax benefit arising from transfer of gratuity funds to Employee Gratuity Trust."

Corporate Governance Update

The company has updated its list of Key Managerial Personnel authorized to determine the materiality of events. The new list includes:

1. Peter Bains as Managing Director and CEO
2. Deepak Jain as CFO
3. Chethan Yogesh as Company Secretary and Compliance Officer

Sustainability Recognition

Syngene was recognized by TIME magazine as one of the World's Most Sustainable Companies, ranking #1 in India among pharma and biotech companies. This accolade underscores the company's commitment to environmental care and social responsibility.

As Syngene International continues to expand its capabilities and global footprint, the strong start to the fiscal year positions the company well for sustained growth in the coming quarters. The management remains confident in their outlook while staying mindful of ongoing macroeconomic factors.